


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Dec-2021
Document Type: USP Monographs
DocId: GUID-83A46579-5F8D-47F3-87EA-2323A4C9AECE_3_en-US
DOI: https://doi.org/10.31003/USPNF_M21850_03_01
DOI Ref: 07jm1

© 2025 USPC
Do not distribute

Dacarbazine



$C_6H_{10}N_6O$ 182.18
1*H*-Imidazole-4-carboxamide, 5-(3,3-dimethyltriaz-1-enyl)-;
5-(3,3-Dimethyltriaz-1-enyl)-1*H*-imidazole-4-carboxamide CAS RN®: 4342-03-04.

DEFINITION
Dacarbazine contains NLT 97.0% and NMT 102.0% of dacarbazine ($C_6H_{10}N_6O$).

[**CAUTION**—Great care should be taken in handling Dacarbazine, as it is a potent cytotoxic agent.]

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197A or 197K
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

- **PROCEDURE**
Protect solutions containing dacarbazine from light and store at 2°–8°.
Solution A: 4.1 g/L of [sodium acetate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of 7.0.
Solution B: 4.1 g/L of [sodium acetate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of 5.5. Mix [acetonitrile](#) and this solution (25:75).
Mobile phase: See [Table 1](#). Return to original conditions, and equilibrate the system for 10 min.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	100	0
10	100	0
20	5	95
23	5	95
25	100	0
35	100	0

Diluent: 0.1 mg/mL of [citric acid](#) in [water](#)
Standard solution: 0.1 mg/mL of [USP Dacarbazine RS](#) in *Diluent*
Sample solution: 0.1 mg/mL of Dacarbazine in *Diluent*
Chromatographic system
(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 250 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Autosampler temperature: 2°–8°

Flow rate: 1.0 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of dacarbazine (C₆H₁₀N₆O) in the portion of Dacarbazine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Dacarbazine RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Dacarbazine in the *Sample solution* (mg/mL)

Acceptance criteria: 97.0%–102.0%

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- **ORGANIC IMPURITIES**

Protect solutions containing dacarbazine and its related compounds from light and store at 2°–8°.

Solution A, Solution B, Mobile phase, and Chromatographic system: Proceed as directed in the Assay.

Diluent: 4.0 mg/mL of [citric acid](#) in [water](#)

Standard stock solution: Use the *Standard solution*, prepared as directed in the Assay.

Standard solution: 4.0 μg/mL of [USP Dacarbazine RS](#) prepared as follows. Transfer a suitable amount of *Standard stock solution* into a volumetric flask and dilute with [water](#).

Dacarbazine related compound A standard solution: 0.04 mg/mL of [USP Dacarbazine Related Compound A RS](#) in [water](#). Sonicate to ensure complete dissolution.

Dacarbazine related compound B standard solution: 0.04 mg/mL of [USP Dacarbazine Related Compound B RS](#) in [water](#). Sonicate to ensure complete dissolution.

Sensitivity solution: 2.0 μg/mL of [USP Dacarbazine RS](#) in [water](#) from *Standard solution*

Sample solution: 4.0 mg/mL of Dacarbazine in *Diluent*. Sonicate to ensure complete dissolution.

System suitability

Samples: *Dacarbazine related compound A standard solution*, *Dacarbazine related compound B standard solution*, and *Sensitivity solution*

Suitability requirements

Relative standard deviation 1: NMT 5.0%, *Dacarbazine related compound A standard solution*

Relative standard deviation 2: NMT 5.0%, *Dacarbazine related compound B standard solution*

Signal-to-noise ratio: ▲NLT ▲ (ERR 1-Dec-2021) 10, *Sensitivity solution*

Analysis

Samples: *Standard solution*, *Dacarbazine related compound A standard solution*, *Dacarbazine related compound B standard solution*, and *Sample solution*

Calculate the percentage of 5-aminoimidazole-4-carboxamide (free base of [USP Dacarbazine Related Compound A RS](#)) in the portion of Dacarbazine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of 5-aminoimidazole-4-carboxamide from the *Sample solution*

r_S = peak response of dacarbazine related compound A from the *Dacarbazine related compound A standard solution*

C_S = concentration of [USP Dacarbazine Related Compound A RS](#) in the *Dacarbazine related compound A standard solution* (mg/mL)

C_U = concentration of Dacarbazine in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of 5-aminoimidazole-4-carboxamide, 126.12

M_{r2} = molecular weight of [USP Dacarbazine Related Compound A RS](#), 162.58

Calculate the percentage of 2-azahypoxanthine (anhydrous) (anhydrous form of [USP Dacarbazine Related Compound B RS](#)) in the portion of Dacarbazine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of 2-azahypoxanthine (anhydrous) from the *Sample solution*

r_S = peak response of dacarbazine related compound B from the *Dacarbazine related compound B standard solution*

C_S = concentration of [USP Dacarbazine Related Compound B RS](#) in the *Dacarbazine related compound B standard solution* (mg/mL)

C_U = concentration of Dacarbazine in the *Sample solution* (mg/mL)

Calculate the percentage of each individual unspecified impurity in the portion of Dacarbazine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each unspecified impurity from the *Sample solution*

r_S = peak response of dacarbazine from the *Standard solution*

C_S = concentration of [USP Dacarbazine RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Dacarbazine in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
5-Aminoimidazole-4-carboxamide ^a	0.28	1.0
2-Azahypoxanthine (anhydrous) ^b	0.45	1.0
Dacarbazine	1.0	—
Any individual unspecified impurity	—	0.10
Total impurities	—	2.0

^a It is the free base of [USP Dacarbazine Related Compound A RS](#) (C₄H₆N₄O).

^b It is the anhydrous form of [USP Dacarbazine Related Compound B RS](#) (C₄H₃N₅O).

• **LIMIT OF DIMETHYLAMINE**

System suitability stock solution A: 20 mg/mL of dimethylamine in [water](#) prepared as follows. Transfer [USP Dimethylamine Solution RS](#) into a suitable volumetric flask and dilute with [water](#) to volume.

System suitability stock solution B: 20 mg/mL of [triethylamine](#) in [water](#)

System suitability solution: *System suitability stock solution A* and *System suitability stock solution B* (1:1). Transfer 5 µL of this solution into a 20-mL headspace vial by syringe through the cap septum.

Standard solution: 10 mg/mL of dimethylamine in [water](#) prepared as follows. Transfer [USP Dimethylamine Solution RS](#) into a suitable volumetric flask and dilute with [water](#) to volume.

Standard: Transfer 5 µL of *Standard solution* into a 20-mL headspace vial by syringe through the cap septum (0.05 mg).

Sample: Transfer 100 mg of Dacarbazine into a 20-mL headspace vial, cap and seal. Add 5 µL of [water](#) by syringe through the cap septum.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: GC

Detector: Flame ionization

Column: 30-m x 0.53-mm; 1.0-µm coating of phase G50

Temperatures

Injection port: 210°

Detector: 300°

Column: See [Table 3](#).

Table 3

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
35	0	35	8
35	40	200	1

Headspace operating parameters: [NOTE—Headspace operating parameters can be modified in order to optimize the performance.]

Temperatures

Oven: 100°

Loop: 110°

Transfer line: 120°

Times

Vial equilibration: 10 min

Pressurization: 0.5 min

Loop fill: 0.25 min

Loop equilibration: 0.05 min

Injection: 0.5 min

Loop size: 1.0 mL

Carrier gas: Helium

Flow rate: 2 mL/min

Injection type: Split, split ratio 25:1

System suitability

Samples: *Standard* and *System suitability solution*

Suitability requirements

Resolution: NLT 1.0 between the dimethylamine and triethylamine peaks, *System suitability solution*

Tailing factor: NMT 2.0, *Standard*

Relative standard deviation: NMT 15.0%, *Standard*

Analysis

Samples: *Standard* and *Sample*

Calculate the percentage of dimethylamine in the portion of Dacarbazine taken:

$$\text{Result} = (r_U/r_S) \times (W_S/W_U) \times 100$$

r_U = peak response of dimethylamine from the *Sample*

r_S = peak response of dimethylamine from the *Standard*

W_S = weight of dimethylamine in the *Standard* (mg)

W_U = weight of Dacarbazine in the *Sample* (mg)

Acceptance criteria: NMT 0.05%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, in a refrigerator.
- **USP REFERENCE STANDARDS (11).**

[USP Dacarbazine RS](#)
[USP Dacarbazine Related Compound A RS](#)
5-Aminoimidazole-4-carboxamide hydrochloride.
 $C_4H_6N_4O \cdot HCl$ 162.58
[USP Dacarbazine Related Compound B RS](#)
2-Azahypoxanthine monohydrate.
 $C_4H_3N_5O \cdot H_2O$ 155.12
[USP Dimethylamine Solution RS](#)
40% of dimethylamine in water
 $(CH_3)_2NH$ 45.09

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DACARBAZINE	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 44(2)

Current DocID: GUID-83A46579-5F8D-47F3-87EA-2323A4C9AECE_3_en-US
DOI: https://doi.org/10.31003/USPNF_M21850_03_01
DOI ref: [07jm1](#)